These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12496910)

  • 1. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B; Holthuis N; Mellström D
    Prostate Cancer Prostatic Dis; 1998 Mar; 1(3):157-162. PubMed ID: 12496910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
    Hammarsten J; Högstedt B
    Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Blood Press; 1999; 8(1):29-36. PubMed ID: 10412880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
    Hammarsten J; Högstedt B
    Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia.
    Ozden C; Ozdal OL; Urgancioglu G; Koyuncu H; Gokkaya S; Memis A
    Eur Urol; 2007 Jan; 51(1):199-203; discussion 204-6. PubMed ID: 16806666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measures of obesity and metabolic syndrome in Indian Americans in northern California.
    Misra KB; Endemann SW; Ayer M
    Ethn Dis; 2006; 16(2):331-7. PubMed ID: 17682232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.
    Tanchoco CC; Cruz AJ; Duante CA; Litonjua AD
    Asia Pac J Clin Nutr; 2003; 12(3):271-6. PubMed ID: 14505989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
    Appel SJ; Harrell JS; Davenport ML
    J Am Acad Nurse Pract; 2005 Dec; 17(12):535-41. PubMed ID: 16293162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome.
    Demir O; Akgul K; Akar Z; Cakmak O; Ozdemir I; Bolukbasi A; Can E; Gumus BH
    Aging Male; 2009 Mar; 12(1):29-34. PubMed ID: 19326294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics.
    Longo-Mbenza B; Nkondi Nsenga J; Vangu Ngoma D
    Int J Cardiol; 2007 Oct; 121(3):229-38. PubMed ID: 17368586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body-mass index, waist-size, waist-hip ratio and cardiovascular risk factors in urban subejcts.
    Gupta R; Rastogi P; Sarna M; Gupta VP; Sharma SK; Kothari K
    J Assoc Physicians India; 2007 Sep; 55():621-7. PubMed ID: 18051732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
    Fu ZF; Liu ML
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(4):260-2. PubMed ID: 19552844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia.
    Dahle SE; Chokkalingam AP; Gao YT; Deng J; Stanczyk FZ; Hsing AW
    J Urol; 2002 Aug; 168(2):599-604. PubMed ID: 12131317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [High risk of atherosclerosis in men aged 20-39 from Lodz agglomeration].
    Słowikowska-Hilczer J; Marchlewska K; Walczak-Jedrzejowska R; Oszukowska E; Gumińska A; Kramek E; Jastrzebska S; Zawadzka E; Kula W; Habib M; Trzuskowska D; Jakubowski L; Kula K
    Pol Merkur Lekarski; 2007 Dec; 23(138):417-25. PubMed ID: 18432124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in the relation of insulin-like growth factor binding protein-1 to cardiovascular risk factors: a population-based study.
    Undén AL; Elofsson S; Brismar K
    Clin Endocrinol (Oxf); 2005 Jul; 63(1):94-102. PubMed ID: 15963068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia.
    Nandeesha H; Koner BC; Dorairajan LN; Sen SK
    Clin Chim Acta; 2006 Aug; 370(1-2):89-93. PubMed ID: 16516184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome.
    Nauck MA; Meier JJ; Wolfersdorff AV; Tillil H; Creutzfeldt W; Köbberling J
    Acta Diabetol; 2003 Dec; 40(4):163-72. PubMed ID: 14740275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.